Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    James Marks, MD, PhD

    TitleProfessor
    SchoolUCSF School of Medicine
    DepartmentAnesthesia/Perioperative Care
    Address1001 Potrero Ave, SFGH 3
    San Francisco CA 94143
    Phone415-206-3256
    Emailmarksj@anesthesia.ucsf.edu

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906.
        View in: PubMed
      2. Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15; 430(2):185-92.
        View in: PubMed
      3. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15; 430(2):141-50.
        View in: PubMed
      4. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80.
        View in: PubMed
      5. McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47.
        View in: PubMed
      6. Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13.
        View in: PubMed
      7. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76.
        View in: PubMed
      8. Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 1; 425(1):28-35.
        View in: PubMed
      9. Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66.
        View in: PubMed
      10. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66.
        View in: PubMed
      11. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53.
        View in: PubMed
      12. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011; 12:58.
        View in: PubMed
      13. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23; 286(51):44218-33.
        View in: PubMed
      14. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15; 421(2):351-61.
        View in: PubMed
      15. Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin avß8-mediated activation of TGF-ß. J Clin Invest. 2011 Jul; 121(7):2863-75.
        View in: PubMed
      16. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011 Mar 15; 71(6):2250-9.
        View in: PubMed
      17. Reddy S, Shaller CC, Doss M, Shchaveleva I, Marks JD, Yu JQ, Robinson MK. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res. 2011 Mar 15; 17(6):1509-20.
        View in: PubMed
      18. Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C, Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, Brown J, Tepp WH, Liu N, Wijesuriya S, Tomic MT, Johnson EA, Smith LA, Marks JD. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011 Mar; 24(3):321-31.
        View in: PubMed
      19. Zhou Y, Zou H, Zhang S, Marks JD. Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J Mol Biol. 2010 Nov 19; 404(1):88-99.
        View in: PubMed
      20. Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS One. 2010; 5(8):e12237.
        View in: PubMed
      21. Diaz L, Mao H, Zhou Y, Kohli M, Cassella J, Santos D, Fesseha Z, Weng K, Chen H, Bamba D, Marks JD, Goldblatt M, Kinch M. TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS. Am J Transl Res. 2010; 2(4):368-80.
        View in: PubMed
      22. Crépin R, Goenaga AL, Jullienne B, Bougherara H, Legay C, Benihoud K, Marks JD, Poul MA. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res. 2010 Jul 1; 70(13):5497-506.
        View in: PubMed
      23. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38.
        View in: PubMed
      24. Lou J, Geren I, Garcia-Rodriguez C, Forsyth CM, Wen W, Knopp K, Brown J, Smith T, Smith LA, Marks JD. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010 Apr; 23(4):311-9.
        View in: PubMed
      25. Darragh MR, Schneider EL, Lou J, Phojanakong PJ, Farady CJ, Marks JD, Hann BC, Craik CS. Tumor detection by imaging proteolytic activity. Cancer Res. 2010 Feb 15; 70(4):1505-12.
        View in: PubMed
      26. Dong J, Thompson AA, Fan Y, Lou J, Conrad F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010 Apr 9; 397(4):1106-18.
        View in: PubMed
      27. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res. 2009 Dec 1; 69(23):8987-95.
        View in: PubMed
      28. Drummond DC, Noble CO, Guo Z, Hayes ME, Connolly-Ingram C, Gabriel BS, Hann B, Liu B, Park JW, Hong K, Benz CC, Marks JD, Kirpotin DB. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2010 Jan 4; 141(1):13-21.
        View in: PubMed
      29. Cheng LW, Stanker LH, Henderson TD, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun. 2009 Oct; 77(10):4305-13.
        View in: PubMed
      30. Ozanich RM, Bruckner-Lea CJ, Warner MG, Miller K, Antolick KC, Marks JD, Lou J, Grate JW. Rapid multiplexed flow cytometric assay for botulinum neurotoxin detection using an automated fluidic microbead-trapping flow cell for enhanced sensitivity. Anal Chem. 2009 Jul 15; 81(14):5783-93.
        View in: PubMed
      31. Warner MG, Grate JW, Tyler A, Ozanich RM, Miller KD, Lou J, Marks JD, Bruckner-Lea CJ. Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron. 2009 Sep 15; 25(1):179-84.
        View in: PubMed
      32. Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN, Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PLoS One. 2009; 4(4):e5355.
        View in: PubMed
      33. Grate JW, Warner MG, Ozanich RM, Miller KD, Colburn HA, Dockendorff B, Antolick KC, Anheier NC, Lind MA, Lou J, Marks JD, Bruckner-Lea CJ. Renewable surface fluorescence sandwich immunoassay biosensor for rapid sensitive botulinum toxin detection in an automated fluidic format. Analyst. 2009 May; 134(5):987-96.
        View in: PubMed
      34. Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B. Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl). 2009 May; 87(5):507-14.
        View in: PubMed
      35. Noble CO, Guo Z, Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, Drummond DC. Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol. 2009 Sep; 64(4):741-51.
        View in: PubMed
      36. Zhou Y, Marks JD. Identification of target and function specific antibodies for effective drug delivery. Methods Mol Biol. 2009; 525:145-60, xv.
        View in: PubMed
      37. Dimitrov DS, Marks JD. Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? Methods Mol Biol. 2009; 525:1-27, xiii.
        View in: PubMed
      38. Shimazaki K, Lepin EJ, Wei B, Nagy AK, Coulam CP, Mareninov S, Fu M, Wu AM, Marks JD, Braun J, Gordon LK, Wadehra M. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res. 2008 Nov 15; 14(22):7367-77.
        View in: PubMed
      39. Leung KM, Feng DX, Lou J, Zhou Y, Fung KP, Waye MM, Tsui SK, Chan PK, Marks JD, Pang SF, Kan YW. Development of human single-chain antibodies against SARS-associated coronavirus. Intervirology. 2008; 51(3):173-81.
        View in: PubMed
      40. Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb 1; 14(3):875-82.
        View in: PubMed
      41. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, Brettin TS. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One. 2007; 2(12):e1271.
        View in: PubMed
      42. Fischer A, Garcia-Rodriguez C, Geren I, Lou J, Marks JD, Nakagawa T, Montal M. Molecular architecture of botulinum neurotoxin E revealed by single particle electron microscopy. J Biol Chem. 2008 Feb 15; 283(7):3997-4003.
        View in: PubMed
      43. Roth A, Drummond DC, Conrad F, Hayes ME, Kirpotin DB, Benz CC, Marks JD, Liu B. Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther. 2007 Oct; 6(10):2737-46.
        View in: PubMed
      44. Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007 Oct; 30(7):684-93.
        View in: PubMed
      45. Hasegawa K, Hu C, Nakamura T, Marks JD, Russell SJ, Peng KW. Affinity thresholds for membrane fusion triggering by viral glycoproteins. J Virol. 2007 Dec; 81(23):13149-57.
        View in: PubMed
      46. Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen. J Immunol. 2007 Sep 1; 179(5):2815-23.
        View in: PubMed
      47. Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer. J Mol Med (Berl). 2007 Oct; 85(10):1113-23.
        View in: PubMed
      48. Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, Marks JD. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. J Mol Biol. 2007 Aug 24; 371(4):934-47.
        View in: PubMed
      49. Goenaga AL, Zhou Y, Legay C, Bougherara H, Huang L, Liu B, Drummond DC, Kirpotin DB, Auclair C, Marks JD, Poul MA. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol. 2007 Jul; 44(15):3777-88.
        View in: PubMed
      50. Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007 Jan; 25(1):107-16.
        View in: PubMed
      51. Hayes ME, Drummond DC, Hong K, Zheng WW, Khorosheva VA, Cohen JA, C O N, Park JW, Marks JD, Benz CC, Kirpotin DB. Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm. 2006 Nov-Dec; 3(6):726-36.
        View in: PubMed
      52. Levy R, Forsyth CM, LaPorte SL, Geren IN, Smith LA, Marks JD. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol. 2007 Jan 5; 365(1):196-210.
        View in: PubMed
      53. Nielsen UB, Kirpotin DB, Pickering EM, Drummond DC, Marks JD. A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunol. 2006; 7:24.
        View in: PubMed
      54. Kehoe JW, Velappan N, Walbolt M, Rasmussen J, King D, Lou J, Knopp K, Pavlik P, Marks JD, Bertozzi CR, Bradbury AR. Using phage display to select antibodies recognizing post-translational modifications independently of sequence context. Mol Cell Proteomics. 2006 Dec; 5(12):2350-63.
        View in: PubMed
      55. Arndt JW, Jacobson MJ, Abola EE, Forsyth CM, Tepp WH, Marks JD, Johnson EA, Stevens RC. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol. 2006 Sep 29; 362(4):733-42.
        View in: PubMed
      56. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC, Park JW. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006 Jul 1; 66(13):6732-40.
        View in: PubMed
      57. Varnum SM, Warner MG, Dockendorff B, Anheier NC, Lou J, Marks JD, Smith LA, Feldhaus MJ, Grate JW, Bruckner-Lea CJ. Enzyme-amplified protein microarray and a fluidic renewable surface fluorescence immunoassay for botulinum neurotoxin detection using high-affinity recombinant antibodies. Anal Chim Acta. 2006 Jun 16; 570(2):137-43.
        View in: PubMed
      58. Hayes ME, Drummond DC, Hong K, Park JW, Marks JD, Kirpotin DB. Assembly of nucleic acid-lipid nanoparticles from aqueous-organic monophases. Biochim Biophys Acta. 2006 Apr; 1758(4):429-42.
        View in: PubMed
      59. Hayes ME, Drummond DC, Kirpotin DB, Zheng WW, Noble CO, Park JW, Marks JD, Benz CC, Hong K. Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther. 2006 Apr; 13(7):646-51.
        View in: PubMed
      60. Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF, Houston LL, Huston JS, Weiner LM. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res. 2006 Mar 1; 12(5):1599-605.
        View in: PubMed
      61. Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD. Isolation of scFvs to in vitro produced extracellular domains of EGFR family members. Cancer Biother Radiopharm. 2005 Dec; 20(6):603-13.
        View in: PubMed
      62. Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol. 2005 Aug 5; 351(1):158-69.
        View in: PubMed
      63. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 2005 Feb 15; 65(4):1471-8.
        View in: PubMed
      64. Nellis DF, Giardina SL, Janini GM, Shenoy SR, Marks JD, Tsai R, Drummond DC, Hong K, Park JW, Ouellette TF, Perkins SC, Kirpotin DB. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog. 2005 Jan-Feb; 21(1):221-32.
        View in: PubMed
      65. Nellis DF, Ekstrom DL, Kirpotin DB, Zhu J, Andersson R, Broadt TL, Ouellette TF, Perkins SC, Roach JM, Drummond DC, Hong K, Marks JD, Park JW, Giardina SL. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog. 2005 Jan-Feb; 21(1):205-20.
        View in: PubMed
      66. Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 2004 Sep 1; 64(17):6200-6.
        View in: PubMed
      67. Marks JD. Medical aspects of biologic toxins. Anesthesiol Clin North America. 2004 Sep; 22(3):509-32, vii.
        View in: PubMed
      68. Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets. 2004 Aug; 8(4):335-53.
        View in: PubMed
      69. Bradbury AR, Marks JD. Antibodies from phage antibody libraries. J Immunol Methods. 2004 Jul; 290(1-2):29-49.
        View in: PubMed
      70. Hall YH, Chaddock JA, Moulsdale HJ, Kirby ER, Alexander FC, Marks JD, Foster KA. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J Immunol Methods. 2004 May; 288(1-2):55-60.
        View in: PubMed
      71. Weaver-Feldhaus JM, Lou J, Coleman JR, Siegel RW, Marks JD, Feldhaus MJ. Yeast mating for combinatorial Fab library generation and surface display. FEBS Lett. 2004 Apr 23; 564(1-2):24-34.
        View in: PubMed
      72. Marks JD. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov Disord. 2004 Mar; 19 Suppl 8:S101-8.
        View in: PubMed
      73. Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C. Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron. J Immunol Methods. 2004 Feb 1; 285(1):99-109.
        View in: PubMed
      74. Liu B, Conrad F, Cooperberg MR, Kirpotin DB, Marks JD. Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 2004 Jan 15; 64(2):704-10.
        View in: PubMed
      75. Marks JD. Antibody affinity maturation by chain shuffling. Methods Mol Biol. 2004; 248:327-43.
        View in: PubMed
      76. Marks JD, Bradbury A. PCR cloning of human immunoglobulin genes. Methods Mol Biol. 2004; 248:117-34.
        View in: PubMed
      77. Marks JD, Bradbury A. Selection of human antibodies from phage display libraries. Methods Mol Biol. 2004; 248:161-76.
        View in: PubMed
      78. Marks JD. Selection of internalizing antibodies for drug delivery. Methods Mol Biol. 2004; 248:201-8.
        View in: PubMed
      79. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003 Jun 15; 63(12):3154-61.
        View in: PubMed
      80. Pavlik P, Siegel RW, Marzari R, Sblattero D, Verzillo V, Collins C, Marks JD, Bradbury A. Predicting antigenic peptides suitable for the selection of phage antibodies. Hum Antibodies. 2003; 12(4):99-112.
        View in: PubMed
      81. Marzari R, Sblattero D, Macor P, Fischetti F, Gennaro R, Marks JD, Bradbury A, Tedesco F. The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies. Eur J Immunol. 2002 Oct; 32(10):2773-82.
        View in: PubMed
      82. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002 Aug 19; 1591(1-3):109-118.
        View in: PubMed
      83. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11346-50.
        View in: PubMed
      84. O'Connell D, Becerril B, Roy-Burman A, Daws M, Marks JD. Phage versus phagemid libraries for generation of human monoclonal antibodies. J Mol Biol. 2002 Aug 2; 321(1):49-56.
        View in: PubMed
      85. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis. 2002 Jul 1; 186(1):64-73.
        View in: PubMed
      86. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002 Apr; 8(4):1172-81.
        View in: PubMed
      87. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002 Mar 15; 317(1):73-83.
        View in: PubMed
      88. Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine. 2002 Feb 22; 20(11-12):1640-8.
        View in: PubMed
      89. Liu B, Huang L, Sihlbom C, Burlingame A, Marks JD. Towards proteome-wide production of monoclonal antibody by phage display. J Mol Biol. 2002 Feb 1; 315(5):1063-73.
        View in: PubMed
      90. Lindquist EA, Marks JD, Kleba BJ, Stephens RS. Phage-display antibody detection of Chlamydia trachomatis-associated antigens. Microbiology. 2002 Feb; 148(Pt 2):443-51.
        View in: PubMed
      91. Mullaney BP, Pallavicini MG, Marks JD. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display. Infect Immun. 2001 Oct; 69(10):6511-4.
        View in: PubMed
      92. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6; 74(1-3):95-113.
        View in: PubMed
      93. Powers DB, Amersdorfer P, Poul M, Nielsen UB, Shalaby MR, Adams GP, Weiner LM, Marks JD. Expression of single-chain Fv-Fc fusions in Pichia pastoris. J Immunol Methods. 2001 May 1; 251(1-2):123-35.
        View in: PubMed
      94. Huie MA, Cheung MC, Muench MO, Becerril B, Kan YW, Marks JD. Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2682-7.
        View in: PubMed
      95. Heitner T, Moor A, Garrison JL, Marks C, Hasan T, Marks JD. Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. J Immunol Methods. 2001 Feb 1; 248(1-2):17-30.
        View in: PubMed
      96. Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function. Biochem Biophys Res Commun. 2001 Jan 12; 280(1):274-9.
        View in: PubMed
      97. Kallet RH, Siobal MS, Alonso JA, Warnecke EL, Katz JA, Marks JD. Lung collapse during low tidal volume ventilation in acute respiratory distress syndrome. Respir Care. 2001 Jan; 46(1):49-52.
        View in: PubMed
      98. Marshall KW, Marks JD. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells. J Immunother. 2001 Jan-Feb; 24(1):27-36.
        View in: PubMed
      99. Nielsen UB, Adams GP, Weiner LM, Marks JD. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 2000 Nov 15; 60(22):6434-40.
        View in: PubMed
      100. Liu B, Marks JD. Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal Biochem. 2000 Nov 1; 286(1):119-28.
        View in: PubMed
      101. Kallet RH, Katz JA, Pittet JF, Ghermey J, Siobal M, Alonso JA, Marks JD. Measuring intra-esophageal pressure to assess transmural pulmonary arterial occlusion pressure in patients with acute lung injury: a case series and review. Respir Care. 2000 Sep; 45(9):1072-84.
        View in: PubMed
      102. Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol. 2000 Sep 1; 301(5):1149-61.
        View in: PubMed
      103. Kallet RH, Jasmer RM, Luce JM, Lin LH, Marks JD. The treatment of acidosis in acute lung injury with tris-hydroxymethyl aminomethane (THAM). Am J Respir Crit Care Med. 2000 Apr; 161(4 Pt 1):1149-53.
        View in: PubMed
      104. Katz JA, Kallet RH, Alonso JA, Marks JD. Improved flow and pressure capabilities of the Datex-Ohmeda SmartVent anesthesia ventilator. J Clin Anesth. 2000 Feb; 12(1):40-7.
        View in: PubMed
      105. Eberhard LW, Morabito DJ, Matthay MA, Mackersie RC, Campbell AR, Marks JD, Alonso JA, Pittet JF. Initial severity of metabolic acidosis predicts the development of acute lung injury in severely traumatized patients. Crit Care Med. 2000 Jan; 28(1):125-31.
        View in: PubMed
      106. Poul MA, Marks JD. Targeted gene delivery to mammalian cells by filamentous bacteriophage. J Mol Biol. 1999 Apr 30; 288(2):203-11.
        View in: PubMed
      107. Becerril B, Poul MA, Marks JD. Toward selection of internalizing antibodies from phage libraries. Biochem Biophys Res Commun. 1999 Feb 16; 255(2):386-93.
        View in: PubMed
      108. Cammarano WB, Pittet JF, Weitz S, Schlobohm RM, Marks JD. Acute withdrawal syndrome related to the administration of analgesic and sedative medications in adult intensive care unit patients. Crit Care Med. 1998 Apr; 26(4):676-84.
        View in: PubMed
      109. Amersdorfer P, Wong C, Chen S, Smith T, Deshpande S, Sheridan R, Finnern R, Marks JD. Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect Immun. 1997 Sep; 65(9):3743-52.
        View in: PubMed
      110. Schier R, McCall A, Adams GP, Marshall KW, Merritt H, Yim M, Crawford RS, Weiner LM, Marks C, Marks JD. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996 Nov 8; 263(4):551-67.
        View in: PubMed
      111. Marks C, Marks JD. Phage libraries--a new route to clinically useful antibodies. N Engl J Med. 1996 Sep 5; 335(10):730-3.
        View in: PubMed
      112. Schier R, Balint RF, McCall A, Apell G, Larrick JW, Marks JD. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene. 1996 Mar 9; 169(2):147-55.
        View in: PubMed
      113. Schier R, Bye J, Apell G, McCall A, Adams GP, Malmqvist M, Weiner LM, Marks JD. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol. 1996 Jan 12; 255(1):28-43.
        View in: PubMed
      114. Schier R, Marks JD. Efficient in vitro affinity maturation of phage antibodies using BIAcore guided selections. Hum Antibodies Hybridomas. 1996; 7(3):97-105.
        View in: PubMed
      115. Schier R, Marks JD, Wolf EJ, Apell G, Wong C, McCartney JE, Bookman MA, Huston JS, Houston LL, Weiner LM, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995 May; 1(1):73-81.
        View in: PubMed
      116. Stackhouse RA, Marks JD, Bainton CR. Performing fiberoptic endotracheal intubation: clinical aspects. Int Anesthesiol Clin. 1994; 32(4):57-73.
        View in: PubMed
      117. Marks JD. Fiberoptic-aided endobronchial intubation. Int Anesthesiol Clin. 1994; 32(4):75-84.
        View in: PubMed
      118. Marks JD, Bainton CR. Practical aspects of fiberoptic laryngobronchoscopy. Int Anesthesiol Clin. 1994; 32(4):31-46.
        View in: PubMed
      119. Hastings RH, Marks JD. Airway management for trauma patients with potential cervical spine injuries. Anesth Analg. 1991 Oct; 73(4):471-82.
        View in: PubMed
      120. Biery DR, Marks JD, Schapera A, Autry M, Schlobohm RM, Katz JA. Factors affecting perioperative pulmonary function in acute respiratory failure. Chest. 1990 Dec; 98(6):1455-62.
        View in: PubMed
      121. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, Montgomery AB, Marks JD, Matthay MA. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest. 1990 Aug; 86(2):474-80.
        View in: PubMed
      122. Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis. 1990 Jan; 141(1):94-7.
        View in: PubMed
      123. Marks JD, Schapera A, Kraemer RW, Katz JA. Pressure and flow limitations of anesthesia ventilators. Anesthesiology. 1989 Sep; 71(3):403-8.
        View in: PubMed
      124. Schapera A, Marks JD, Minagi H, Goodman P, Katz JA. Perioperative pulmonary function in acute respiratory failure: effect of ventilator type and gas mixture. Anesthesiology. 1989 Sep; 71(3):396-402.
        View in: PubMed
      125. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis. 1988 Jul; 138(1):62-8.
        View in: PubMed
      James's Networks
      Click the "See All" links for more information and interactive visualizations!
      Related Concepts
      Derived automatically from this person's publications.
      See all (493) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (21) people
      _
      Related Authors
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Back to TOP